Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Access Program of Bardoxolone Methyl in Chronic Kidney Disease
jRCT2080225140Phase 3Completed
- Sponsor
- Reata Pharmaceuticals
- Start
- Mar 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of bardoxolone methyl in chronic kidney disease (CKD), sponsored by Reata Pharmaceuticals. Primary endpoint: Long-term safety and tolerability of bardoxolone methyl. Started Mar 2020; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080225140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225140.